- Home
- PYXS vs RAND Comparison
PYXS vs RAND Comparison
Compare PYXS & RAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYXS
- RAND
- Stock Information
- Founded
- PYXS 2018
- RAND 1969
- Country
- PYXS United States
- RAND United States
- Employees
- PYXS N/A
- RAND N/A
- Industry
- PYXS Biotechnology: Pharmaceutical Preparations
- RAND Finance: Consumer Services
- Sector
- PYXS Health Care
- RAND Finance
- Exchange
- PYXS Nasdaq
- RAND Nasdaq
- Market Cap
- PYXS 76.1M
- RAND 80.9M
- IPO Year
- PYXS 2021
- RAND N/A
- Fundamental
- Price
- PYXS $1.28
- RAND $28.10
- Analyst Decision
- PYXS Strong Buy
- RAND
- Analyst Count
- PYXS 6
- RAND 0
- Target Price
- PYXS $9.20
- RAND N/A
- AVG Volume (30 Days)
- PYXS 551.2K
- RAND 17.6K
- Earning Date
- PYXS 03-20-2025
- RAND 03-04-2025
- Dividend Yield
- PYXS N/A
- RAND 17.90%
- EPS Growth
- PYXS N/A
- RAND 123.39
- EPS
- PYXS N/A
- RAND 4.98
- Revenue
- PYXS $16,146,000.00
- RAND $8,351,941.00
- Revenue This Year
- PYXS N/A
- RAND N/A
- Revenue Next Year
- PYXS N/A
- RAND N/A
- P/E Ratio
- PYXS N/A
- RAND $5.64
- Revenue Growth
- PYXS N/A
- RAND 16.96
- 52 Week Low
- PYXS $1.23
- RAND $13.69
- 52 Week High
- PYXS $6.85
- RAND $31.89
- Technical
- Relative Strength Index (RSI)
- PYXS 32.91
- RAND 78.59
- Support Level
- PYXS $1.23
- RAND $22.77
- Resistance Level
- PYXS $1.40
- RAND $28.00
- Average True Range (ATR)
- PYXS 0.09
- RAND 1.67
- MACD
- PYXS 0.00
- RAND 0.42
- Stochastic Oscillator
- PYXS 15.15
- RAND 61.64
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, diversified management company. The firm's investment objectives is to maximize the total return to the shareholders with current income combined with capital appreciation. Some of its portfolios include lumious, and GiveGab among others.